Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, open-label, randomised, phase III trial comparing Velcade [bortezomib]/dexamethasone versus vincristine/Adriamycin (Doxorubicin)/dexamethasone (VAD) for the treatment of patients with multiple myeloma

Next Previous
X
Search
Trial Profile

A multicentre, open-label, randomised, phase III trial comparing Velcade [bortezomib]/dexamethasone versus vincristine/Adriamycin (Doxorubicin)/dexamethasone (VAD) for the treatment of patients with multiple myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Vincristine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Aug 2013 The European Commission has approved bortezomib induction therapy in combination with dexamethasone or thalidomide + dexamethasone based on the analysis of data from this trial, according to a Janssen-Cilag media release.
    • 28 Jun 2013 Data from this study support a postive opinion from the CHMP of the EMA for bortezomib-based induction regimens, according to a Janssen Cilag media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top